monsitj
Canaccord Genuity has cut Vertex Pharmaceuticals (NASDAQ:VRTX) to sell, citing a recent run-up in the stock price in the wake of positive data for the company’s neuropathic pain drug VX-548.
Canaccord said it now estimates the probability of success for